OphthaliX completes CF101 preclinical studies on Anterior Uveitis

Apr 10 2012

OphthaliX (OTCBB: OPLI) announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published results showing the efficacy of CF101 in preventing Posterior Uveitis, strongly support the utilization of CF101 as a drug candidate for the treatment of patients with Anterior or Posterior Uveitis and as such address a larger market than either alone. This market exceeds 200,000 patients and therefore CF101 does not fall in the FDA definition of an orphan drug for the Uveitis clinical application.

Prof. Pnina Fishman, interim CEO and Chairman of OphthaliX commented: "We are very pleased with the successful preclinical study which provides additional proof for the efficacy of CF101 in Uveitis and paves the way for a larger patient population to be treated with the drug upon successful clinical development. This will also be reflected in a larger potential market for CF101. We are currently conducting all the preparatory work for a phase 2 study in Uveitis in addition to the ongoing studies in Dry Eye Syndrome and Glaucoma. Although anterior uveitis is most often treated with topical medication, the excellent safety profile of CF101 suggests it could have a very favorable therapeutic index as a novel oral therapy in this disease."